The first hair relaxer cancer trial in the United States has ended in a settlement.

L'Oréal USA and several other manufacturers reached a confidential settlement on November 16 with four women who claimed that years of using hair relaxers contributed to their cancer diagnoses.

The agreement came just one week after jury selection began in Cook County, Illinois. Financial terms were not disclosed.

While the settlement resolves only four individual cases, it arrives as more than 12,700 similar lawsuits remain pending in federal court.

Cancer Claims Settled Before Jury Verdict

The plaintiffs, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, filed their lawsuits in Illinois state court in 2023 and 2024.

The women alleged that repeated exposure to chemicals in hair relaxers contributed to their development of gynecologic cancers, including uterine and ovarian cancer.

Their claims involved products sold by L'Oréal USA and other manufacturers, including brands historically marketed to Black women.

Jury selection began November 9, but the parties reached an agreement before jurors could determine whether the products caused the women's illnesses.

According to Reuters' November 16 report, the settlement amount remains confidential.

L'Oréal continues to defend the safety of its hair care products, including those sold under the SoftSheen-Carson brand.

The company maintains that its products undergo rigorous scientific safety evaluations and comply with applicable regulations.

The settlement does not constitute an admission of wrongdoing or establish that any particular product caused cancer.

Significance of the Settlement For Other Cancer Claimants

As of November 2, 2026, the U.S. Judicial Panel on Multidistrict Litigation reported 12,743 pending lawsuits consolidated in the Northern District of Illinois under MDL No. 3060.

These cases involve allegations that chemical hair relaxers increased the risk of uterine cancer, ovarian cancer and other reproductive health conditions.

Unlike the four Cook County cases, the federal lawsuits are being coordinated through multidistrict litigation, a process that allows courts to handle common evidence and pretrial issues efficiently.

The first federal bellwether trial is scheduled for September 2027.

Bellwether trials are representative cases used to help both sides evaluate how juries may respond to evidence. Their outcomes can influence settlement negotiations without deciding the remaining lawsuits.

The Illinois settlement could provide an early indication that manufacturers are willing to resolve certain claims before risking jury verdicts.

But four confidential settlements do not establish a compensation formula for other plaintiffs or guarantee a broader agreement, and no global hair relaxer settlement has been announced.

Research Linking Hair Relaxers to Cancer Remains Central to Litigation

The lawsuits gained national attention following a 2022 study by researchers at the National Institutes of Health.

Published in the Journal of the National Cancer Institute, the study examined hair product use among more than 33,000 women.

Researchers found that women who frequently used chemical hair straighteners had more than twice the risk of developing uterine cancer compared with women who reported never using the products.

The researchers estimated that approximately 1.64% of women who never used hair straighteners would develop uterine cancer by age 70, compared with 4.05% of frequent users.

The findings were particularly significant because chemical relaxers have historically been widely marketed to and used by Black women.

However, the study identified an association rather than proving that hair relaxers directly cause cancer.

Scientists continue to investigate which ingredients or chemical exposures may contribute to the observed risks.

Manufacturers have challenged the research, arguing that epidemiological findings do not establish that their products caused individual cancer diagnoses.

Federal Judge Allows Key Cancer Expert Testimony

The Illinois settlement also follows significant rulings concerning the scientific evidence that plaintiffs can present in federal court.

On October 22, U.S. District Judge Mary M. Rowland allowed an epidemiologist to testify that chemical hair relaxers are capable of causing uterine and ovarian cancer.

The judge found that the expert's scientific methodology was sufficiently reliable for consideration in the federal litigation.

However, she also restricted portions of another expert's proposed testimony, demonstrating that courts are examining the scientific evidence individually rather than accepting every opinion offered by the plaintiffs.

Additional expert-evidence rulings followed in November as the federal cases continued moving toward trial.

These decisions address whether scientific testimony may be presented to juries. They do not establish that hair relaxers caused any particular woman's cancer.

Could More Hair Relaxer Settlements Follow?

The first trial settlement offers an important development for women pursuing cancer claims, but several questions remain unanswered.

Because the settlement terms are confidential, there's no public indication of how much compensation each woman received or what factors influenced the agreement.

The resolution also provides no jury findings that could guide future cases.

The broader litigation continues to involve disputes over product formulations, exposure histories, scientific evidence and whether individual cancer diagnoses can be attributed to particular products.

Still, the November 16 agreement marks the first reported resolution of hair relaxer cancer claims after a trial began.

With thousands of cases pending and federal bellwether trials approaching, future court decisions and settlement negotiations will determine whether the Illinois agreement becomes an early step toward broader resolutions or remains an isolated settlement.

References:

Reuters. L'Oréal US Settles Hair Relaxer Cancer Cases During First Trial. November 16, 2026.

Allure. Settlements Reached in Key Lawsuits About Chemical Hair Straighteners' Link to Cancer. November 17, 2026.

U.S. Judicial Panel on Multidistrict Litigation. MDL Statistics Report: Distribution of Pending MDL Dockets by District. November 2, 2026.

U.S. District Court for the Northern District of Illinois. In re Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation. MDL No. 3060. Memorandum Opinions and Orders, October 22 and November 12, 2026.

Chang, C.J., et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. Journal of the National Cancer Institute. 2022.

National Institutes of Health. Hair Straightening Chemicals Associated With Higher Uterine Cancer Risk. October 17, 2022.